Acelyrin Q2 2023 Earnings Report
Key Takeaways
ACELYRIN reported its Q2 2023 financial results, highlighting clinical and corporate milestones, including new data from the Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa and the completion of enrollment in the Phase 2b/3 trial of izokibep in Psoriatic Arthritis. The company's strong cash position of $823.0 million, including gross proceeds from a recent IPO of $621.0 million, is expected to support multiple late-stage clinical programs.
New data from Part A of Phase 2b/3 trial of izokibep in Hidradenitis Suppurativa demonstrated improvements in number of draining tunnels in two-thirds of patients as early as week 4.
Enrollment completed in Phase 2b/3 randomized controlled trial of izokibep in Psoriatic Arthritis; top-line data now accelerated to first quarter 2024 from mid-2024.
Strong cash position of $823.0 million, including gross proceeds from recent IPO of $621.0 million, supports multiple late-stage clinical programs through key milestones across all three clinical programs.
Ken Lock appointed as Chief Commercial Officer.